Profile data is unavailable for this security.
About the company
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care includes advanced solutions for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories and personalized services for individuals with a stoma. Its Continence and Critical Care includes products and services for people with urinary continence issues, and other devices for critical care. Its Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
- Revenue in GBP (TTM)1.72bn
- Net income in GBP104.69m
- Incorporated2016
- Employees10.13k
- LocationConvaTec Group PLC7th Floor, 20 Eastbourne TerraceLONDON W2 6LGUnited KingdomGBR
- Websitehttps://www.convatecgroup.com/
Mergers & acquisitions
| Acquired company | CTEC:LSE since announced | Transaction value |
|---|---|---|
| 30 Technology Ltd-Antimicrobial Nitric Oxide Platform | 28.87% | 218.66m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GN Store Nord A/S | 2.08bn | 26.20m | 2.93bn | 7.17k | 110.32 | 2.57 | 12.78 | 1.41 | 1.53 | 1.53 | 130.43 | 65.84 | 0.5919 | 2.96 | 4.28 | 2,528,960.00 | 0.8688 | 4.91 | 1.57 | 7.44 | 49.55 | 53.29 | 1.47 | 6.82 | 0.4812 | 1.88 | 0.5847 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
| Ambu A/S | 562.73m | 27.35m | 2.99bn | 4.70k | 122.65 | 5.43 | 43.73 | 5.30 | 0.9014 | 0.9014 | 18.71 | 20.36 | 0.7075 | 2.00 | 7.26 | 1,060,875.00 | 3.44 | 3.81 | 3.97 | 4.62 | 56.97 | 59.37 | 4.86 | 5.43 | 1.30 | 7.20 | 0.1038 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| Getinge AB | 2.34bn | 177.05m | 3.99bn | 11.74k | 24.13 | 1.93 | 13.33 | 1.71 | 8.85 | 8.85 | 116.85 | 110.75 | 0.6027 | 2.74 | 5.78 | 2,711,219.00 | 4.60 | 5.31 | 6.09 | 6.98 | 45.54 | 47.83 | 7.64 | 8.69 | 0.776 | 14.05 | 0.2099 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Ypsomed Holding AG | 448.62m | 63.87m | 4.48bn | 2.20k | 70.03 | 8.85 | 33.97 | 9.98 | 5.31 | 5.31 | 37.31 | 42.03 | 0.5888 | 4.92 | 5.75 | 247,016.00 | 8.38 | 4.44 | 12.70 | 6.77 | 32.04 | 26.95 | 14.24 | 6.87 | 0.5577 | 30.61 | 0.2614 | 18.54 | 7.02 | 1.31 | 121.92 | -0.3034 | 20.32 | -1.47 |
| SCHOTT Pharma AG & Co KgaA | 776.50m | 135.57m | 4.87bn | 4.65k | 35.91 | 7.89 | 27.43 | 6.27 | 1.05 | 1.05 | 6.01 | 4.78 | -- | -- | -- | 194,928.30 | -- | -- | -- | -- | 35.23 | -- | 17.48 | -- | 1.08 | -- | 0.094 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| ConvaTec Group PLC | 1.72bn | 104.69m | 5.75bn | 10.13k | 55.00 | 4.23 | 20.74 | 3.34 | 0.051 | 0.051 | 0.8386 | 0.6635 | 0.5865 | 2.57 | 6.14 | 169,943.10 | 3.57 | 2.36 | 4.18 | 2.73 | 56.04 | 76.98 | 6.08 | 4.34 | 0.8835 | 2.65 | 0.4367 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| Amplifon SpA | 1.94bn | 133.02m | 5.98bn | 14.38k | 44.70 | 6.32 | 16.54 | 3.09 | 0.6898 | 0.6898 | 10.02 | 4.88 | 0.6219 | 20.99 | 10.38 | 157,179.50 | 4.27 | 4.31 | 6.16 | 5.81 | 23.56 | 59.01 | 6.86 | 7.28 | 0.4519 | 6.31 | 0.5795 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Carl Zeiss Meditec AG | 1.80bn | 237.29m | 7.40bn | 4.82k | 31.16 | -- | 105.78 | 4.12 | 3.10 | 3.10 | 23.45 | -- | -- | -- | -- | 434,177.70 | -- | 9.56 | -- | 11.72 | 57.35 | 57.84 | 13.28 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| Demant A/S | 2.58bn | 293.26m | 7.97bn | 21.62k | 27.44 | 7.48 | -- | 3.09 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Smith & Nephew plc | 4.46bn | 211.31m | 8.38bn | 18.45k | 39.60 | 1.99 | 11.03 | 1.88 | 0.242 | 0.242 | 5.11 | 4.81 | 0.5562 | 0.7522 | 4.33 | 241,624.50 | 2.64 | 4.10 | 3.29 | 4.99 | 68.82 | 71.39 | 4.74 | 8.02 | 0.72 | 4.84 | 0.3715 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | -8.12 |
| Holder | Shares | % Held |
|---|---|---|
| Black Creek Investment Management, Inc.as of 15 Aug 2023 | 103.24m | 5.04% |
| Artisan Partners LPas of 31 Dec 2022 | 97.98m | 4.78% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2022 | 97.42m | 4.75% |
| Schroder Investment Management Ltd.as of 02 Apr 2024 | 57.57m | 2.81% |
| The Vanguard Group, Inc.as of 02 Apr 2024 | 56.05m | 2.73% |
| Massachusetts Financial Services Co.as of 02 Apr 2024 | 48.62m | 2.37% |
| FIL Investment Advisors (UK) Ltd.as of 02 Apr 2024 | 44.95m | 2.19% |
| abrdn Investment Management Ltd.as of 31 Dec 2022 | 43.37m | 2.12% |
| BlackRock Investment Management (UK) Ltd.as of 15 May 2023 | 39.63m | 1.93% |
| Marathon Asset Management Ltd.as of 02 Apr 2024 | 39.28m | 1.92% |
